Table 1.
Patient Characteristics.
| Neuropathological Tumor Type (WHO 2016) | Neuropathological Tumor Grade (WHO 2016) | MGMPR Promoter Methylation Status |
Age | Gender |
|---|---|---|---|---|
| Diffuse astrocytoma, IDH-mutant | WHO grade II | Methylated | 23 | M |
| Diffuse astrocytoma, IDH-mutant | WHO grade II | Methylated | 33 | M |
| Diffuse astrocytoma, IDH-mutant | WHO grade II | Unmethylated | 54 | F |
| Diffuse astrocytoma, IDH-mutant | WHO grade II | Methylated | 77 | F |
| Diffuse astrocytoma, IDH-mutant | WHO grade II | Methylated | 46 | F |
| Diffuse astrocytoma, IDH-mutant | WHO grade II | Unmethylated | 57 | M |
| Diffuse astrocytoma, IDH-wildtype | WHO grade II | Unmethylated | 27 | M |
| Anaplastic astrocytoma, IDH-mutant | WHO grade III | Unmethylated | 59 | M |
| Anaplastic astrocytoma, IDH-mutant | WHO grade III | Methylated | 29 | M |
| Anaplastic astrocytoma, IDH-mutant | WHO grade III | Methylated | 28 | F |
| Anaplastic astrocytoma, IDH-wildtype | WHO grade III | Unmethylated | 65 | F |
| Glioblastoma, IDH-mutant | WHO grade IV | Methylated | 45 | F |
| Glioblastoma, IDH-wildtype | WHO grade IV | Unmethylated | 47 | F |
| Glioblastoma, IDH-wildtype | WHO grade IV | Unmethylated | 58 | M |
| Glioblastoma, IDH-wildtype | WHO grade IV | Unmethylated | 59 | F |
| Glioblastoma, IDH-wildtype | WHO grade IV | Methylated | 52 | M |
| Glioblastoma, IDH-wildtype | WHO grade IV | Unmethylated | 59 | M |
| Glioblastoma, IDH-wildtype | WHO grade IV | Methylated | 71 | M |
| Glioblastoma, IDH-wildtype | WHO grade IV | Methylated | 61 | M |
| Glioblastoma, IDH-wildtype | WHO grade IV | Methylated | 62 | M |
| Oligoendroglioma, IDH-mutant and 1p/19q-codeleted | WHO grade II | Methylated | 52 | M |
| Oligoendroglioma, IDH-mutant and 1p/19q-codeleted | WHO grade II | Methylated | 38 | F |
| Oligoendroglioma, IDH-mutant and 1p/19q-codeleted | WHO grade II | Methylated | 61 | M |
| Anaplastic oligodendroglioma, IDH-mutant and 1p/19q-codeleted | WHO grade III | Methylated | 51 | M |